Drugs / DARGISTOTUG
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04457778 | Jul 2020 → Jun 2023 | metastatic neoplasm | EMD Serono Research & Development Institute, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05327530 | Aug 2022 → Jun 2025 overdue | urothelial carcinoma | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DARGISTOTUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314667 ↗ |
| Known as | M6223 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04457778 ↗ |
| Action | Inhibit | “M6223, an inhibitor of TIGIT” NCT04457778 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314667 ↗ |
| Route | Intravenous | “Participants received an intravenous (IV) infusion of M6223” NCT04457778 ↗ |
| Target | TIGIT | “M6223, an inhibitor of TIGIT” NCT04457778 ↗ |